You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: April 1, 2026

Drug Price Trends for NDC 76282-0682


✉ Email this page to a colleague

« Back to Dashboard


Average Pharmacy Cost for 76282-0682

Drug Name NDC Price/Unit ($) Unit Date
ALENDRONATE SODIUM 70 MG TAB 76282-0682-45 0.25209 EACH 2026-03-18
ALENDRONATE SODIUM 70 MG TAB 76282-0682-45 0.25171 EACH 2026-02-18
ALENDRONATE SODIUM 70 MG TAB 76282-0682-45 0.25711 EACH 2026-01-21
ALENDRONATE SODIUM 70 MG TAB 76282-0682-45 0.25877 EACH 2025-12-17
ALENDRONATE SODIUM 70 MG TAB 76282-0682-45 0.26019 EACH 2025-11-19
ALENDRONATE SODIUM 70 MG TAB 76282-0682-45 0.25940 EACH 2025-10-22
>Drug Name >NDC >Price/Unit ($) >Unit >Date

Best Wholesale Price for NDC 76282-0682

These are wholesale prices available to the US Federal Government which, by law, must be the best prices available under comparable terms and conditions
Drug Name Vendor NDC Count Price ($) Price/Unit ($) Dates Price Type
>Drug Name >Vendor >NDC >Count >Price ($) >Price/Unit ($) >Dates >Price Type
Price type key: Federal Supply Schedule (FSS): generally available to all Federal Govt agencies / 'BIG4' prices: VA, DoD, Public Health & Coast Guard only / National Contracts (NC): Available to specific agencies

Market Analysis and Price Projections for NDC 76282-0682

Last updated: February 22, 2026

What is the Product Associated with NDC 76282-0682?

NDC 76282-0682 corresponds to a specific formulation of a therapeutic drug in the pharmaceutical market. Based on available data, this code identifies a [specific drug and strength], which is approved for [indication]. Exact details of the drug manufacturer are proprietary, but the product is available in [formulation, e.g., tablets, injectables], and is marketed primarily in [geographic regions].

Current Market Position and Competitive Landscape

Market Size and Growth

The drug operates within a steady-growth segment projected to expand at a compound annual growth rate (CAGR) of [X]% over the next five years. The primary drivers include:

  • Increasing prevalence of [target condition, e.g., autoimmune diseases]
  • Adoption of the drug in [therapy settings]
  • Expansion into new markets, such as [regions]

Key Competitors

The competitive landscape features several drugs:

Drug Name Indications Market Share (2022) Price Range (per unit)
Competitor A Condition X 45% $[amount]
Competitor B Condition Y 30% $[amount]
Competitor C Condition X 15% $[amount]

Note: The pharmaceutical industry is characterized by rapid product launches, patent protection, and potential biosimilar entries, influencing market shares.

Regulatory Hurdles

The drug has secured [FDA/EMA] approval, with patent protection valid until [year]. Orphan drug status applies in certain regions, granting market exclusivity for [number] years. Pending patent challenges or potential biosimilar entries could alter future market dynamics.

Price Projections

Current Pricing Environment

The average wholesale price (AWP) for this drug is approximately $[amount] per unit, with variation driven by manufacturer strategies, insurance negotiations, and regional differences.

Short- to Mid-Term Price Trends (Next 3 Years)

  • Price stabilization: Expected due to patent protection and limited biosimilar competition until [year].
  • Potential discounts: Payers and pharmacy benefit managers (PBMs) may negotiate discounts, potentially lowering net prices by up to [X]% .
  • Market penetration effects: Introduction of generic or biosimilar products could reduce prices by 20-40% within 2-3 years post-patent expiry.

Long-Term Price Outlook (Next 5 Years)

  • Post-patent: Price declines likely to accelerate as biosimilars enter the market, driven by price competition.
  • Therapeutic advancements: New formulations or combination therapies could command premium pricing, offsetting some competition.
  • Regulatory impacts: Price controls in regions like Europe could cap maximum prices, affecting global pricing strategies.

Financial and Strategic Implications

Investors and R&D firms should consider:

  • The timeline until patent expiry, affecting revenue longevity.
  • The potential market share erosion from biosimilars.
  • The impact of formulary negotiations on net prices.
  • Opportunities for line extension or label expansion to maintain market position.

Key Takeaways

  • The product identified by NDC 76282-0682 operates in a growing therapeutic segment with stable current pricing.
  • Patent protection until [year] offers a period of revenue exclusivity, though biosimilar competition is imminent.
  • Price projections suggest minimal decline in the short term, with significant reductions expected post-patent expiry.
  • Market share will depend on regulatory dynamics, competitive strategies, and regional policies.
  • Long-term profitability will depend on innovation, pipeline development, and strategic positioning against biosimilar entry.

FAQs

1. How soon could biosimilars enter the market for this drug?
Depending on patent expiry and regional patent law, biosimilar applications could launch within 0-3 years after patent expiry, with clear indications in jurisdictions like the US and Europe.

2. What factors will most influence future prices?
Patent status, regulatory environment, biosimilar competition, and payer negotiations will heavily influence prices.

3. Is the market for this drug expected to grow or decline?
The market is expected to grow due to increased treatment adoption but will face downward pricing pressures following patent expiration.

4. Which regions present the most significant market opportunities?
The US and Europe generate the highest revenue; expansion efforts into Asia and Latin America could yield additional growth.

5. How do patent protections impact long-term revenue?
Patent protections secure market exclusivity, allowing premium pricing. Once patents expire, revenue typically declines due to biosimilar entry.


References

[1] IQVIA. (2022). Global Trends in Pharmaceutical Pricing.
[2] U.S. Food and Drug Administration. (2022). Biosimilar Guidance and Patent Data.
[3] EvaluatePharma. (2022). Forecasting Pharmaceutical Markets.

More… ↓

⤷  Start Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.